The combination of suPAR and SCr even statistically outperformed combinations of SCr with damage biomarkers such as albuminuria or KIM-1, and was more or less equivalent to SCr combined with NGAL, the latter, however, being an additional leukocyte- and liver-derived biomarker in sepsis rather than an independent kidney damage biomarker (30–32). The gene discussed is LCN2; the disease is Sepsis.